find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Genito-Urinary
NA
Accepting Patients
nct/study# NCT04329767 / ISI-IRIS-002
Intuitive Surgical, Protocol: ISI-IRIS-002 , PI: Dr. Stifelman, Title: A Prospective Post-Market Study To Evaluate The Clinical Utility Of IRISTM, A Three-Dimensional (3-D) Anatomical Modeling Software For Pre-Operative Surgical Planning And Intra-Operative Navigation For Nephrectomy
Learn More
Genito-Urinary
Phase III
Accepting Patients
nct/study# NCT03775265 / S1806
Phase III Randomized Trial Of Concurrent Chemoradiotherapy With Or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer
Learn More
Genito-Urinary
Phase III
Accepting Patients
nct/study# NCT03678025 / S1802
Phase III Randomized Trial Of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) Of The Primary Tumor In Metastatic Prostate Cancer
Learn More
Genito-Urinary
Phase I/II
Accepting Patients
nct/study# NCT03288545 / SGN22E-002
A Study Of Enfortumab Vedotin (ASG-22CE) As Monotherapy Or In Combination With Other Anticancer Therapies For The Treatment Of Urothelial Cancer
Learn More
Genito-Urinary
Phase III
Accepting Patients
nct/study# NCT04197986 / QBGJ398-302
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Of Infigratinib For The Adjuvant Treatment Of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Learn More
Head and Neck
Phase III
Accepting Patients
nct/study# NCT04199104 / MK-7902-010-01
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study Of Pembrolizumab (MK-3475) With Or Without Lenvatinib (E7080/MK-7902) To Evaluate The Safety And Efficacy Of Pembrolizumab And Lenvatinib As 1L Intervention In A PD-L1 Selected Population Of Participants With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.